002: The Biopharma Exit Strategy With Dr. Francois Nader
We love to hear from our listeners. Send us a message. Every emerging biopharma company shares a common goal: creating value for its employees, its board, its investors, and ultimately, patients. Along the way, that value creation might get a boost from an IPO, a merger, an acquisition, or steady growth as a private entity. On this episode of The Business Of Biotech, we talk with Dr. Francois Nader—a man who's orchestrated several wildly successful biotech exits—about why it's imperative to begin with the end in mind, and how to navigate your options when the time is right.Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: [email protected] Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/
Sign in
